Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • FAQs

    Global Drug Discovery Services Market size was valued at USD 4.64 Billion in 2024 and is poised to grow from USD 5.01 Billion in 2025 to USD 9.28 Billion by 2033, growing at a CAGR of 8% during the forecast period (2026–2033).

    The drug discovery services market is fragmented with large number of companies that operate at both at a local and global level. The key strategies adopted by leaders in the drug discovery services industry include acquisitions & mergers or investments and partnership with other product manufacturers. The development strategies of pharmaceutical companies are based on market trends and intelligence. They partner with research institutions and Contract Research Organizations (CRO) to study certain diseases for specific populations. Hence, growing pharmaceutical companies funding for new drug discovery is driving the growth of the market. Additionally, innovative drug development and launch are expected to propel the market growth.  'Charles River Laboratories (USA)', 'WuXi AppTec (China) ', 'Thermo Fisher Scientific Inc. (USA) ', 'Evotec SE (Germany) ', 'Pharmaron (China) ', 'Labcorp (USA) ', 'Syngene International Limited (India) ', 'Eurofins Scientific (Luxembourg) ', 'Jubilant Biosys Limited (India) ', 'Curia Global, Inc. (USA) ', 'GenScript (USA) ', 'Frontage Holdings Corporation (USA) ', 'Piramal Enterprises Ltd. (India) ', 'Aragen Life Sciences Ltd. (India) ', 'Sygnature Discovery (UK) ', 'Selvita SA (Poland) ', 'Viva Biotech (China) ', 'TCG Lifesciences Pvt. Ltd. (India) ', 'Medicilon (China) ', 'Sai Life Sciences Limited (India)'

    Chronic diseases like diabetes, dementia, and cardiovascular disease are responsible for more than 40 million fatalities each year, they make up seven of every ten deaths globally. This increase in chronic disease incidence is expected to boost the global drug discovery services market size throughout forecast period. Increasing chronic diseases are creating new economic opportunities for companies providing drug discovery services as there is a greater demand for medications.  

    Growing Number of Novel Therapies: Imminent demand for novel medicine development, emerging need pertaining to rapid growth in healthcare sector across globe is fueling drug discovery services market growth. High prevalence of chronic diseases is pushing government & pharmaceutical establishments for solutions and have started spending more on clinical trials. Thus, rise in demand for drug discovery services will be high.

    North America is dominating the drug discovery services market with the largest share and is anticipated to witness considerable growth over the forecast period. The drug discovery services market is expected to be propelled by the number of CROs and CMOs in the region, alongside the indenture of several top biopharmaceutical and pharmaceutical companies. North America patents most of the new drugs Due to the growing incidences of several chronic diseases and rising elderly people population in US, the market is expected to grow. Chronic disease affects an estimated 60% of the population, with chronic conditions comprising one or more such diseases in approximately half the US population. The rising awareness about the biologics is fueling demand for innovative drugs in the region, thereby supporting North America drug discovery services market growth.  

    Feedback From Our Clients

    Global Drug Discovery Services Market

    Report ID: SQMIG35J2059

    $5,300
    BUY NOW